Effect of mutations in LDLR and PCSK9 genes on phenotypic variability in Tunisian familial hypercholesterolemia patients

被引:23
|
作者
Slimani, Afef [1 ]
Jelassi, Awatef [1 ]
Jguirim, Imen [1 ]
Najah, Mohamed [1 ]
Rebhi, Lamia [2 ]
Omezzine, Asma [2 ]
Maatouk, Faouzi [3 ]
Ben Hamda, Khaldoun [3 ]
Kacem, Maha [4 ]
Rabes, Jean-Pierre [5 ]
Abifadel, Marianne [6 ]
Boileau, Catherine [5 ,7 ]
Rouis, Mustapha [8 ]
Slimane, Mohamed Naceur [1 ]
Varret, Mathilde [7 ]
机构
[1] Fac Med, Unit Res Genet & Biol Factors Atherosclerosis, Monastir 5000, Tunisia
[2] Sahloul Univ Hosp, Dept Biochem, URMSP 28 04, Sousse, Tunisia
[3] Fattouma Bourguiba Hosp, Dept Cardiovasc Dis, Monastir 5000, Tunisia
[4] Farhat Hachad Hosp, Dept Endocrinol, Sousse, Tunisia
[5] Univ Versailles St Quentin En Yvelines, Hop A Pare, AP HP, Versailles, France
[6] Univ St Joseph, Fac Pharm, Beirut, Lebanon
[7] Univ Paris Denis Diderot, CHU Xavier Bichat, INSERM, U698, Paris, France
[8] Univ Paris 06, UMR Physiol & Physiopathol 7079, Paris, France
关键词
Familial hypercholesterolemia; LDLR gene; PCSK9; gene; Phenotypic variability; APOLIPOPROTEIN-E; CHOLESTEROL LEVELS; POLYMORPHISMS; SPECTRUM; VARIANT;
D O I
10.1016/j.atherosclerosis.2012.02.018
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Autosomal dominant hypercholesterolemia (ADH) is commonly caused by mutations in the low-density lipoprotein (LDL) receptor gene (LDLR), in the apolipoprotein B-100 gene (APOB), or in the proprotein convertase subtilisin kexine 9 gene (PCSK9). ADH subjects carrying a mutation in LDLR present highly variable plasma LDL-cholesterol (LDL-C). This variability might be due to environmental factors or the effect of some modifying genes such as PCSK9 and APOE. Aims: We investigated the molecular basis of thirteen Tunisian ADH families and attempted to determine the impact of PCSK9 and APOE gene variations on LDL-cholesterol levels and on the variable phenotypic expression of the disease. Methods and results: Fifty six subjects were screened for mutations in the LDLR gene through direct sequencing. The causative mutation was found to segregate with the disease in each family and a new frameshift mutation, p.Met767CysfsX21, was identified in one family. The distribution of total-and LDL-cholesterol levels, adjusted for age and gender, among homozygous and heterozygous ADH patients varied widely. Within seven families, nine subjects presented low LDL-cholesterol levels despite carrying a mutation in the LDLR gene. To identify the molecular actors underlying this phenotypic variability, the PCSK9 gene was screened using direct sequencing and/or enzymatic restriction analysis, and the apo E genotypes were determined. A new missense variation (p.Pro174Ser) in the PCSK9 gene was identified and characterized as a new putative loss-of-function mutation. Conclusion: Genetic variations in PCSK9 and APOE genes could explain only part of the variability observed in the phenotypic expression in Tunisian ADH patients carrying mutations in the LDLR gene. Other genetic variants and environmental factors very probably act to fully explain this phenotypic variability. (C) 2012 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码:158 / 166
页数:9
相关论文
共 50 条
  • [31] PLASMA IDOL, SOLUBLE LDLR AND PCSK9 LEVELS AS POTENTIAL BIOMARKERS OF FAMILIAL HYPERCHOLESTEROLEMIA IN CHILDREN
    Girona, J.
    Rodriguez-Borjabad, C.
    Ibarretxe, D.
    Heras, M.
    Amigo, N.
    Feliu, A.
    Masana, L.
    Plana, N.
    ATHEROSCLEROSIS, 2018, 275 : E22 - E22
  • [32] Effect of a splice site mutation in LDLR gene and two variations in PCSK9 gene in Tunisian families with familial hypercholesterolaemia
    Jelassi, A.
    Slimani, A.
    Jguirim, I.
    Najah, M.
    Maatouk, F.
    Varret, M.
    Slimane, M. N.
    ANNALS OF CLINICAL BIOCHEMISTRY, 2011, 48 : 83 - 86
  • [33] Phenotypic variability in 4 homozygous familial hypercholesterolemia siblings compound heterozygous for LDLR mutations
    Rabacchi, Claudio
    Bigazzi, Federico
    Puntoni, Mariarita
    Sbrana, Francesco
    Sampietro, Tiziana
    Tarugi, Patrizia
    Bertolini, Stefano
    Calandra, Sebastiano
    JOURNAL OF CLINICAL LIPIDOLOGY, 2016, 10 (04) : 944 - 952
  • [34] PCSK9 AND LDLRAP1 SEQUENCING ANALYSIS IN SUBJECTS WITH FAMILIAL HYPERCHOLESTEROLEMIA AND NEITHER MUTATION IN LDLR NOR APOB GENES
    Civeira, F.
    Tejedor, T.
    Stef, M.
    Palacios, L.
    Mateo-Gallego, R.
    Lamiquiz, I.
    de Castro-Oros, I.
    Cenarro, A.
    ATHEROSCLEROSIS, 2014, 235 (02) : E55 - E55
  • [35] PLASMATIC AND PHENOTYPIC EFFECTS WITH ALIROCUMAB, A PCSK9 INHIBITOR, IN FAMILIAL HYPERCHOLESTEROLEMIA TREATMENT (FH)
    Simonelli, Francesca
    Miotti, Cristiano
    Filice, Barbara Fausta
    Gallo, Giovanna
    Burocchi, Simone
    Presta, Vivanne
    Salerno, Gerardo
    Abbolito, Sofia
    Volpe, Massimo
    De Biase, Luciano
    ATHEROSCLEROSIS, 2017, 263 : E246 - E247
  • [36] A Decision Aid for the Use of PCSK9 Inhibitors in Patients With Familial Hypercholesterolemia
    Farwati, Medhat
    Shaw, Kevin
    Hargraves, Ian G.
    Montori, Victor M.
    Kullo, Iftikhar J.
    CIRCULATION, 2018, 138
  • [37] How many familial hypercholesterolemia patients are eligible for PCSK9 inhibition?
    Masana, Luis
    Plana, Nuria
    Perez-Calahorra, Sofia
    Ibarretxe, Daiana
    Lamiquiz-Moneo, Itziar
    Pedro-Botet, Juan
    Suarez-Tembra, Manuel
    Valdivielso, Pedro
    Ortega, Emilio
    Civeira, Fernando
    ATHEROSCLEROSIS, 2017, 262 : 107 - 112
  • [38] Methylation status of LDLR, PCSK9 and LDLRAP1 is associated with cardiovascular events in familial hypercholesterolemia
    Marcal, Elisangela da Silva Rodrigues
    Borges, Jessica Bassani
    Bastos, Gisele Medeiros
    Hirata, Thiago Dominguez Crespo
    de Oliveira, Victor Fernandes
    Goncalves, Rodrigo Marques
    Faludi, Andre Arpad
    Franca, Joao Italo Dias
    Silva, Daiana Vitor de Oliveira
    Malaquias, Vanessa Barbosa
    Luchessi, Andre Ducati
    Silbiger, Vivian Nogueira
    Nakazone, Marcelo Arruda
    Carmo, Tayanne Silva
    Silva Souza, Doroteia Rossi
    Sampaio, Marcelo Ferraz
    Hirata, Rosario Dominguez Crespo
    Hirata, Mario Hiroyuki
    EPIGENOMICS, 2024, 16 (11-12) : 809 - 820
  • [39] PCSK9 inhibitors in familial hypercholesterolemia: What is the evidence?
    Paquette, Martine
    Hegele, Robert A.
    Baass, Alexis
    JOURNAL OF CLINICAL LIPIDOLOGY, 2018, 12 (05) : 1106 - 1108
  • [40] PCSK9 inhibition in patients with hypercholesterolemia
    Desai, Nihar R.
    Sabatine, Marc S.
    TRENDS IN CARDIOVASCULAR MEDICINE, 2015, 25 (07) : 567 - 574